Sialyl-Tn in cancer: (How) did we miss the target?

Biomolecules

Volumn 2, Issue 4, 2012, Pages 435-466

  Julien, Sylvain ^a   Videira, Paula A ^b   Delannoy, Philippe ^a  

^a UNIVERSITÉ DES SCIENCES ET TECHNOLOGIES DE LILLE   (France)

^b NOVA MEDICAL SCHOOL   (Portugal)

Author keywords

Cancer immunotherapy; O glycan; Sialyl Tn antigen; ST6GalNAc I; Theratope

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CARBOHYDRATE ANTIGEN; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; GLYCAN; HERMES ANTIGEN; MUCIN 1; SIALYL TN ANTIGEN; SIALYLTRANSFERASE; THERATOPE; TN ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

BIOSYNTHESIS; BREAST METASTASIS; CANCER INVASION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL HETEROGENEITY; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG TOLERABILITY; GENE EXPRESSION; GENE MUTATION; GLYCOSYLATION; HISTOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; INCIDENCE; INJECTION SITE ULCER; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); NEOPLASM; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 85016347273     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom2040435     Document Type: Review

References (172)

1. Rajpert-De Meyts, E.; Poll, S.N.; Goukasian, I.; Jeanneau, C.; Herlihy, A.S.; Bennett, E.P.; Skakkebaek, N.E.; Clausen, H.; Giwercman, A.; Mandel, U. Changes in the profile of simple mucin-type O-glycans and polypeptide GalNAc-transferases in human testis and testicular neoplasms are associated with germ cell maturation and tumour differentiation. Virchows Arch. 2007, 451, 805-814.
2. Marcos, N.T.; Pinho, S.; Grandela, C.; Cruz, A.; Samyn-Petit, B.; Harduin-Lepers, A.; Almeida, R.; Silva, F.; Morais, V.; Costa, J.; Kihlberg, J.; Clausen, H.; Reis, C.A. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res. 2004, 64, 7050-7057.
3. Harduin-Lepers, A.; Vallejo-Ruiz, V.; Krzewinski-Recchi, M.A.; Samyn-Petit, B.; Julien, S.; Delannoy, P. The human sialyltransferase family. Biochimie 2001, 83, 727-737.
4. Sewell, R.; Bäckström, M.; Dalziel, M.; Gschmeissner, S.; Karlsson, H.; Noll, T.; Gätgens, J.; Clausen, H.; Hansson, G.C.; Burchell, J.; Taylor-Papadimitriou, J. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J. Biol. Chem. 2006, 281, 3586-3594.
5. Marcos, N.T.; Bennett, E.P.; Gomes, J.; Magalhaes, A.; Gomes, C.; David, L.; Dar, I.; Jeanneau, C.; DeFrees, S.; Krustrup, D.; Vogel, L.K.; Kure, E.H.; Burchell, J.; Taylor-Papadimitriou, J.; Clausen, H.; Mandel, U.; Reis, C.A. ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Front Biosci. (Elite Ed.) 2011, 3, 1443-1455.
6. Julien, S.; Adriaenssens, E.; Ottenberg, K.; Furlan, A.; Courtand, G.; Vercoutter-Edouart, A.-S.; Hanisch, F.-G.; Delannoy, P.; Le Bourhis, X. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology 2006, 16, 54-64.
7. Ju, T.; Cummings, R.D. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc. Natl. Acad. Sci. USA 2002, 99, 16613-16618.
8. Ju, T.; Lanneau, G.S.; Gautam, T.; Wang, Y.; Xia, B.; Stowell, S.R.; Willard, M.T.; Wang, W.; Xia, J.Y.; Zuna, R.E.; Laszik, Z.; Benbrook, D.M.; Hanigan, M.H.; Cummings, R.D. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res. 2008, 68, 1636-1646.
9. Yoo, N.J.; Kim, M.S.; Lee, S.H. Absence of COSMC gene mutations in breast and colorectal carcinomas. APMIS 2008, 116, 154-155.
10. Nuti, M.; Teramoto, Y.A.; Mariani-Costantini, R.; Hand, P.H.; Colcher, D.; Schlom, J. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int. J. Cancer 1982, 29, 539-545.
11. Reddish, M.A.; Jackson, L.; Koganty, R.R.; Qiu, D.; Hong, W.; Longenecker, B.M. Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes. Glycoconj. J. 1997, 14, 549-560.
12. Ching, C.K.; Holmes, S.W.; Holmes, G.K.; Long, R.G. Comparison of two sialosyl-Tn binding monoclonal antibodies (MLS102 and B72.3) in detecting pancreatic cancer. Gut 1993, 34, 1722-1725.
13. Kurosaka, A.; Kitagawa, H.; Fukui, S.; Numata, Y.; Nakada, H.; Funakoshi, I.; Kawasaki, T.; Ogawa, T.; Iijima, H.; Yamashina, I. A monoclonal antibody that recognizes a cluster of a disaccharide, NeuAc alpha(2----6)GalNAc, in mucin-type glycoproteins. J. Biol. Chem. 1988, 263, 8724-8726.
14. Kjeldsen, T.; Clausen, H.; Hirohashi, S.; Ogawa, T.; Iijima, H.; Hakomori, S. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2-6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res. 1988, 48, 2214-2220.
15. Ogata, S.; Koganty, R.; Reddish, M.; Longenecker, B.M.; Chen, A.; Perez, C.; Itzkowitz, S.H. Different modes of sialyl-Tn expression during malignant transformation of human colonic mucosa. Glycoconj. J. 1998, 15, 29-35.
16. Terasawa, K.; Furumoto, H.; Kamada, M.; Aono, T. Expression of Tn and sialyl-Tn antigens in the neoplastic transformation of uterine cervical epithelial cells. Cancer Res. 1996, 56, 2229-2232.
17. Thor, A.; Ohuchi, N.; Szpak, C.A.; Johnston, W.W.; Schlom, J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. 1986, 46, 3118-3124.
18. Stanick, D.; Schuss, A.; Mishriki, Y.; Chao, S.; Thor, A.; Lundy, J. Reactivity of the monoclonal antibody B72.3 with fetal antigen: correlation with expression of TAG-72 in human carcinomas. Cancer Invest. 1988, 6, 279-287.
19. Itzkowitz, S.H.; Yuan, M.; Montgomery, C.K.; Kjeldsen, T.; Takahashi, H.K.; Bigbee, W.L.; Kim, Y.S. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 1989, 49, 197-204.
20. Pistolesi, S.; Nuti, M.; Castagna, M.; Pingitore, R. Mammary fetal gland: identification of new oncofetal antigens by monoclonal antibodies B72.3, MM1.80 and 4.36. Tumori 2001, 87, 252-255.
21. Baldus, S.E.; Hanisch, F.G.; Schwonzen, M.; Nakahara, Y.; Iijima, H.; Ogawa, T.; Peter-Katalinic, J.; Uhlenbruck, G. Monoclonal antibody SP-21 defines a sialosyl-Tn antigen expressed on carcinomas and K562 erythroleukemia cells. Anticancer Res. 1992, 12, 1935-1940.
22. Cao, Y.; Stosiek, P.; Springer, G.F.; Karsten, U. Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Histochem. Cell Biol. 1996, 106, 197-207.
23. Itoh, T.; Yonezawa, S.; Nomoto, M.; Ueno, K.; Kim, Y.S.; Sato, E. Expression of mucin antigens and Lewis X-related antigens in carcinomas and dysplasia of the pharynx and larynx. Pathol. Int. 1996, 46, 646-655.
24. Kirkeby, S.; Moe, D.; Bardow, A. MUC1 and the simple mucin-type antigens: Tn and Sialyl-Tn are differently expressed in salivary gland acini and ducts from the submandibular gland, the vestibular folds, and the soft palate. Arch. Oral Biol. 2010, 55, 830-841.
25. Kakeji, Y.; Maehara, Y.; Morita, M.; Matsukuma, A.; Furusawa, M.; Takahashi, I.; Kusumoto, T.; Ohno, S.; Sugimachi, K. Correlation between sialyl Tn antigen and lymphatic metastasis in patients with Borrmann type IV gastric carcinoma. Br. J. Cancer 1995, 71, 191-195.
26. Victorzon, M.; Nordling, S.; Nilsson, O.; Roberts, P.J.; Haglund, C. Sialyl Tn antigen is an independent predictor of outcome in patients with gastric cancer. Int. J. Cancer 1996, 65, 295-300.
27. Imada, T.; Rino, Y.; Hatori, S.; Takahashi, M.; Amano, T.; Kondo, J.; Suda, T. Sialyl Tn antigen expression is associated with the prognosis of patients with advanced colorectal cancer. Hepatogastroenterology 1999, 46, 208-214.
28. Jass, J.R.; Allison, L.J.; Edgar, S.G. Distribution of sialosyl Tn and Tn antigens within normal and malignant colorectal epithelium. J. Pathol. 1995, 176, 143-149.
29. Cao, Y.; Karsten, U.; Otto, G.; Bannasch, P. Expression of MUC1, Thomsen-Friedenreich antigen, Tn, sialosyl-Tn, and alpha2,6-linked sialic acid in hepatocellular carcinomas and preneoplastic hepatocellular lesions. Virchows Arch. 1999, 434, 503-509.
30. Siddiki, B.; Ho, J.J.; Huang, J.; Byrd, J.C.; Lau, E.; Yuan, M.; Kim, Y.S. Monoclonal antibody directed against colon cancer mucin has high specificity for malignancy. Int. J. Cancer 1993, 54, 467-474.
31. Itzkowitz, S.; Kjeldsen, T.; Friera, A.; Hakomori, S.; Yang, U.S.; Kim, Y.S. Expression of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology 1991, 100, 1691-1700.
32. Lyubsky, S.; Madariaga, J.; Lozowski, M.; Mishriki, Y.; Schuss, A.; Chao, S.; Lundy, J. A tumor-associated antigen in carcinoma of the pancreas defined by monoclonal antibody B72.3. Am. J. Clin. Pathol. 1988, 89, 160-167.
33. Carrilho, C.; Cantel, M.; Gouveia, P.; David, L. Simple mucin-type carbohydrate antigens (Tn, sialosyl-Tn, T and sialosyl-T) and gp 230 mucin-like glycoprotein are candidate markers for neoplastic transformation of the human cervix. Virchows Arch. 2000, 437, 173-179.
34. Tashiro, Y.; Yonezawa, S.; Kim, Y.S.; Sato, E. Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. Hum. Pathol. 1994, 25, 364-372.
35. Ghazizadeh, M.; Ogawa, H.; Sasaki, Y.; Araki, T.; Aihara, K. Mucin carbohydrate antigens (T, Tn, and sialyl-Tn) in human ovarian carcinomas: relationship with histopathology and prognosis. Hum. Pathol. 1997, 28, 960-966.
36. Numa, F.; Tsunaga, N.; Michioka, T.; Nawata, S.; Ogata, H.; Kato, H. Tissue expression of Sialyl Tn antigen in gynecologic tumors. J. Obstet. Gynaecol. (Tokyo 1995) 1995, 21, 385-389.
37. Ogawa, H.; Ghazizadeh, M.; Araki, T. Tn and sialyl-Tn antigens as potential prognostic markers in human ovarian carcinoma. Gynecol. Obstet. Invest. 1996, 41, 278-283.
38. Hachiya, T.; Honda, T.; Kubo, K.; Sekiguchi, M. Expression patterns of type II pneumocyte apical surface glycoconjugates in lung adenocarcinoma cells. Virchows Arch. 1999, 434, 63-69.
39. Cho, S.H.; Sahin, A.; Hortobagyi, G.N.; Hittelman, W.N.; Dhingra, K. Sialyl-Tn antigen expression occurs early during human mammary carcinogenesis and is associated with high nuclear grade and aneuploidy. Cancer Res. 1994, 54, 6302-6305.
40. Schmitt, F.C.; Figueiredo, P.; Lacerda, M. Simple mucin-type carbohydrate antigens (T, sialosyl-T, Tn and sialosyl-Tn) in breast carcinogenesis. Virchows Arch. 1995, 427, 251-258.
41. Reed, W.; Bryne, M.; Clausen, H.; Dabelsteen, E.; Nesland, J.M. Simple mucins (T, sialosyl-T, Tn and sialosyl-Tn) are not diagnostic for malignant breast lesions. Anticancer Res. 1994, 14, 609-615.
42. Baldus, S.E.; Zirbes, T.K.; Mönig, S.P.; Engel, S.; Monaca, E.; Rafiqpoor, K.; Hanisch, F.G.; Hanski, C.; Thiele, J.; Pichlmaier, H.; Dienes, H.P. Histopathological subtypes and prognosis of gastric cancer are correlated with the expression of mucin-associated sialylated antigens: Sialosyl-Lewis(a), Sialosyl-Lewis(x) and sialosyl-Tn. Tumour Biol. 1998, 19, 445-453.
43. Cao, Y.; Schlag, P.M.; Karsten, U. Immunodetection of epithelial mucin (MUC1, MUC3) and mucin-associated glycotopes (TF, Tn, and sialosyl-Tn) in benign and malignant lesions of colonic epithelium: apolar localization corresponds to malignant transformation. Virchows Arch. 1997, 431, 159-166.
44. Castagna, M.; Nuti, M.; Squartini, F. Mammary cancer antigen recognized by monoclonal antibody B72.3 in apocrine metaplasia of the human breast. Cancer Res. 1987, 47, 902-906.
45. Schmitt, F.C.; Marinho, A.; Amendoeira, I. Expression of sialyl-Tn in fine-needle aspirates from mammographically detected breast lesions: a marker of malignancy? Diagn. Cytopathol. 1998, 18, 325-329.
46. Kim, G.E.; Bae, H.-I.; Park, H.-U.; Kuan, S.-F.; Crawley, S.C.; Ho, J.J.L.; Kim, Y.S. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology 2002, 123, 1052-1060.
47. Hruban, R.H.; Goggins, M.; Parsons, J.; Kern, S.E. Progression model for pancreatic cancer. Clin. Cancer Res. 2000, 6, 2969-2972.
48. Barresi, G.; Giuffrè, G.; Vitarelli, E.; Grosso, M.; Tuccari, G. The immunoexpression of Tn, sialyl-Tn and T antigens in chronic active gastritis in relation to Helicobacter pylori infection. Pathology 2001, 33, 298-302.
49. Cohen, M.; Drut, R.; Cueto Rúa, E. SIALYL-Tn antigen distribution in Helicobacter pylori chronic gastritis in children: an immunohistochemical study. Pediatr. Pathol. Mol. Med. 2003, 22, 117-129.
50. Karlén, P.; Young, E.; Broström, O.; Löfberg, R.; Tribukait, B.; Ost, K.; Bodian, C.; Itzkowitz, S. Sialyl-Tn antigen as a marker of colon cancer risk in ulcerative colitis: relation to dysplasia and DNA aneuploidy. Gastroenterology 1998, 115, 1395-1404.
51. Ta, A.; Harpaz, N.; Bodian, C.; Roston, A.; Oberman, L.; Chen, A.; Itzkowitz, S. Sialyl-tn antigen expression in Crohn's colitis. Inflam. Bowel Dis. 1997, 3, 254-259.
52. Federici, M.F.; Kudryashov, V.; Saigo, P.E.; Finstad, C.L.; Lloyd, K.O. Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: serous and mucinous tumors exhibit distinctive patterns of expression. Int. J. Cancer 1999, 81, 193-198.
53. Pinto, R.; Carvalho, A.S.; Conze, T.; Magalhães, A.; Picco, G.; Burchell, J.M.; Taylor-Papadimitriou, J.; Reis, C.A.; Almeida, R.; Mandel, U.; Clausen, H.; Söderberg, O.; David, L. Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ Proximity Ligation. J. Cell. Mol. Med. 2011, 16, 1474-1484.
54. Flucke, U.; Zirbes, T.K.; Schröder, W.; Mönig, S.P.; Koch, V.; Schmitz, K.; Thiele, J.; Dienes, H.P.; Hölscher, A.H.; Baldus, S.E. Expression of mucin-associated carbohydrate core antigens in esophageal squamous cell carcinomas. Anticancer Res. 2001, 21, 2189-2193.
55. López-Ferrer, A.; Barranco, C.; de Bolós, C. Differences in the O-glycosylation patterns between lung squamous cell carcinoma and adenocarcinoma. Am. J. Clin. Pathol. 2002, 118, 749-755.
56. Ching, C.K.; Holmes, S.W.; Holmes, G.K.; Long, R.G. Blood-group sialyl-Tn antigen is more specific than Tn as a tumor marker in the pancreas. Pancreas 1994, 9, 698-702.
57. Contegiacomo, A.; Alimandi, M.; Muraro, R.; Pizzi, C.; Calderopoli, R.; De Marchis, L.; Sgambato, A.; Pettinato, G.; Petrella, G.; De Filippo, M.R. Expression of epitopes of the tumour-associated glycoprotein 72 and clinicopathological correlations in mammary carcinomas. Eur. J. Cancer 1994, 30A, 813-820.
58. Johnston, W.W.; Szpak, C.A.; Thor, A.; Schlom, J. Phenotypic characterization of lung cancers in fine needle aspiration biopsies using monoclonal antibody B72.3. Cancer Res. 1986, 46, 6462-6470.
59. Lottich, S.C.; Johnston, W.W.; Szpak, C.A.; Delong, E.R.; Thor, A.; Schlom, J. Tumor-associated antigen TAG-72: correlation of expression in primary and metastatic breast carcinoma lesions. Breast Cancer Res. Treat. 1985, 6, 49-56.
60. Ohuchi, N.; Thor, A.; Nose, M.; Fujita, J.; Kyogoku, M.; Schlom, J. Tumor-associated glycoprotein (TAG-72) detected in adenocarcinomas and benign lesions of the stomach. Int. J. Cancer 1986, 38, 643-650.
61. Sasaki, M.; Yamato, T.; Nakanuma, Y. Expression of sialyl-Tn, Tn and T antigens in primary liver cancer. Pathol. Int. 1999, 49, 325-331.
62. Szpak, C.A.; Johnston, W.W.; Roggli, V.; Kolbeck, J.; Lottich, S.C.; Vollmer, R.; Thor, A.; Schlom, J. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am. J. Pathol. 1986, 122, 252-260.
63. Ohshio, G.; Yoshioka, H.; Manabe, T.; Sakahara, H.; Yamabe, H.; Imamura, M.; Inoue, M.; Tanaka, N.; Nakada, H.; Yamashina, I. Expression of sialosyl-Tn antigen (monoclonal antibody MLS102 reactive) in normal tissues and malignant tumors of the digestive tract. J. Cancer Res. Clin. Oncol. 1994, 120, 325-330.
64. Miles, D.W.; Linehan, J.; Smith, P.; Filipe, I. Expression of sialyl-Tn in gastric cancer: correlation with known prognostic factors. Br. J. Cancer 1995, 71, 1074-1076.
65. Terashima, S.; Takano, Y.; Ohori, T.; Kanno, T.; Kimura, T.; Motoki, R.; Kawaguchi, T. Sialyl-Tn antigen as a useful predictor of poor prognosis in patients with advanced stomach cancer. Surg. Today 1998, 28, 682-686.
66. Imai, J.; Ghazizadeh, M.; Naito, Z.; Asano, G. Immunohistochemical expression of T, Tn and sialyl-Tn antigens and clinical outcome in human breast carcinoma. Anticancer Res. 2001, 21, 1327-1334.
67. Leivonen, M.; Nordling, S.; Lundin, J.; von Boguslawski, K.; Haglund, C. STn and prognosis in breast cancer. Oncology 2001, 61, 299-305.
68. Lin, J.-C.; Liao, S.-K.; Lee, E.-H.; Hung, M.-S.; Sayion, Y.; Chen, H.-C.; Kang, C.-C.; Huang, L.-S.; Cherng, J.-M. Molecular events associated with epithelial to mesenchymal transition of nasopharyngeal carcinoma cells in the absence of Epstein-Barr virus genome. J. Biomed. Sci. 2009, 16, 105.
69. Davidson, B.; Berner, A.; Nesland, J.M.; Risberg, B.; Kristensen, G.B.; Tropé, C.G.; Bryne, M. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. Hum. Pathol. 2000, 31, 1081-1087.
70. Kinney, A.Y.; Sahin, A.; Vernon, S.W.; Frankowski, R.F.; Annegers, J.F.; Hortobagyi, G.N.; Buzdar, A.U.; Frye, D.K.; Dhingra, K. The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer 1997, 80, 2240-2249.
71. Miles, D.W.; Happerfield, L.C.; Smith, P.; Gillibrand, R.; Bobrow, L.G.; Gregory, W.M.; Rubens, R.D. Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer. Br. J. Cancer 1994, 70, 1272-1275.
72. Takahashi, I.; Maehara, Y.; Kusumoto, T.; Yoshida, M.; Kakeji, Y.; Kusumoto, H.; Furusawa, M.; Sugimachi, K. Predictive value of preoperative serum sialyl Tn antigen levels in prognosis of patients with gastric cancer. Cancer 1993, 72, 1836-1840.
73. Nakagoe, T.; Sawai, T.; Tsuji, T.; Jibiki, M.-A.; Nanashima, A.; Yamaguchi, H.; Yasutake, T.; Ayabe, H.; Arisawa, K.; Ishikawa, H. Predictive factors for preoperative serum levels of sialy Lewis(x), sialyl Lewis(a) and sialyl Tn antigens in gastric cancer patients. Anticancer Res. 2002, 22, 451-458.
74. Werther, J.L.; Tatematsu, M.; Klein, R.; Kurihara, M.; Kumagai, K.; Llorens, P.; Guidugli Neto, J.; Bodian, C.; Pertsemlidis, D.; Yamachika, T.; Kitou, T.; Itzkowitz, S. Sialosyl-Tn antigen as a marker of gastric cancer progression: an international study. Int. J. Cancer 1996, 69, 193-199.
75. Ma, X.C.; Terata, N.; Kodama, M.; Jancic, S.; Hosokawa, Y.; Hattori, T. Expression of sialyl-Tn antigen is correlated with survival time of patients with gastric carcinomas. Eur. J. Cancer 1993, 29A, 1820-1823.
76. Imada, T.; Rino, Y.; Takahashi, M.; Hatori, S.; Shiozawa, M.; Amano, T.; Kondo, J. Serum CA 19-9, SLX, STN and CEA levels of the peripheral and the draining venous blood in gastric cancer. Hepatogastroenterology 1999, 46, 2086-2090.
77. Ikeda, Y.; Mori, M.; Kamakura, T.; Saku, M.; Sugimachi, K. Immunohistochemical expression of sialyl Tn and sialyl Lewis(a) antigens in stromal tissue correlates with peritoneal dissemination in stage IV human gastric cancer. Eur. J. Surg. Oncol. 1995, 21, 168-175.
78. Ozaki, H.; Matsuzaki, H.; Ando, H.; Kaji, H.; Nakanishi, H.; Ikehara, Y.; Narimatsu, H. Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model. Clin. Exp. Metastasis 2012, 29, 229-238.
79. Davidson, B.; Gotlieb, W.H.; Ben-Baruch, G.; Kopolovic, J.; Goldberg, I.; Nesland, J.M.; Berner, A.; Bjåmer, A.; Bryne, M. Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases-A clinicopathologic study. Gynecol. Oncol. 2000, 77, 35-43.
80. Itzkowitz, S.H.; Bloom, E.J.; Kokal, W.A.; Modin, G.; Hakomori, S.; Kim, Y.S. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990, 66, 1960-1966.
81. Julien, S.; Lagadec, C.; Krzewinski-Recchi, M.-A.; Courtand, G.; Le Bourhis, X.; Delannoy, P. Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration. Breast Cancer Res. Treat. 2005, 90, 77-84.
82. Motoo, Y.; Kawakami, H.; Watanabe, H.; Satomura, Y.; Ohta, H.; Okai, T.; Makino, H.; Toya, D.; Sawabu, N. Serum sialyl-Tn antigen levels in patients with digestive cancers. Oncology 1991, 48, 321-326.
83. Sato, T.; Nishimura, G.; Nonomura, A.; Miwa, K.; Miyazaki, I. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer. Hepatogastroenterology 1999, 46, 914-919.
84. Nanashima, A.; Yamaguchi, H.; Nakagoe, T.; Matsuo, S.; Sumida, Y.; Tsuji, T.; Sawai, T.; Yamaguchi, E.; Yasutake, T.; Ayabe, H. High serum concentrations of sialyl Tn antigen in carcinomas of the biliary tract and pancreas. J. Hepatobiliary Pancreat. Surg. 1999, 6, 391-395.
85. Inoue, M.; Ogawa, H.; Nakanishi, K.; Tanizawa, O.; Karino, K.; Endo, J. Clinical value of sialyl Tn antigen in patients with gynecologic tumors. Obstet. Gynecol. 1990, 75, 1032-1036.
86. Kobayashi, H.; Terao, T.; Kawashima, Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J. Clin. Oncol. 1992, 10, 95-101.
87. Kudoh, K.; Kikuchi, Y.; Kita, T.; Tode, T.; Takano, M.; Hirata, J.; Mano, Y.; Yamamoto, K.; Nagata, I. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. Gynecol. Obstet. Invest. 1999, 47, 52-57.
88. Nakagoe, T.; Sawai, T.; Tsuji, T.; Jibiki, M.; Nanashima, A.; Yamaguchi, H.; Yasutake, T.; Ayabe, H.; Arisawa, K.; Ishikawa, H. Pre-operative serum levels of sialyl Tn antigen predict liver metastasis and poor prognosis in patients with gastric cancer. Eur. J. Surg. Oncol. 2001, 27, 731-739.
89. Maeda, K.; Chung, Y.; Onoda, N.; Nakanishi, I.; Nitta, A.; Arimoto, Y.; Yamada, N.; Kondo, Y.; Kato, Y.; Sowa, M. Serum sialyl-tn antigen level as a prognostic indicator in patients with gastric-cancer. Int. J. Oncol. 1994, 4, 129-132.
90. Nakagoe, T.; Sawai, T.; Tsuji, T.; Jibiki, M.; Nanashima, A.; Yamaguchi, H.; Kurosaki, N.; Yasutake, T.; Ayabe, H.; Tagawa, Y. Prognostic value of circulating sialyl Tn antigen in colorectal cancer patients. Anticancer Res. 2000, 20, 3863-3869.
91. D'Amico, T.A.; Aloia, T.A.; Moore, M.B.; Herndon, J.E., 2nd; Brooks, K.R.; Lau, C.L.; Harpole, D.H., Jr Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann. Thorac. Surg. 2000, 69, 882-886.
92. Ikeda, Y.; Kuwano, H.; Baba, K.; Ikebe, M.; Matushima, T.; Adachi, Y.; Mori, M.; Sugimachi, K. Expression of Sialyl-Tn antigens in normal squamous epithelium, dysplasia, and squamous cell carcinoma in the esophagus. Cancer Res. 1993, 53, 1706-1708.
93. Takano, Y.; Teranishi, Y.; Terashima, S.; Motoki, R.; Kawaguchi, T. Lymph node metastasis-related carbohydrate epitopes of gastric cancer with submucosal invasion. Surg. Today 2000, 30, 1073-1082.
94. Tsuchiya, A.; Kikuchi, Y.; Ando, Y.; Abe, R. Correlation between expression of sialosyl-T antigen and survival in patients with gastric cancer. Br. J. Surg. 1995, 82, 960-962.
95. Nakagoe, T.; Sawai, T.; Tsuji, T.; Jibiki, M.; Nanashima, A.; Yamaguchi, H.; Kurosaki, N.; Yasutake, T.; Ayabe, H. Circulating sialyl Lewis(x), sialyl Lewis(a), and sialyl Tn antigens in colorectal cancer patients: multivariate analysis of predictive factors for serum antigen levels. J. Gastroenterol. 2001, 36, 166-172.
96. Vierbuchen, M.J.; Fruechtnicht, W.; Brackrock, S.; Krause, K.T.; Zienkiewicz, T.J. Quantitative lectin-histochemical and immunohistochemical studies on the occurrence of alpha(2,3)-and alpha(2,6)-linked sialic acid residues in colorectal carcinomas. Relation to clinicopathologic features. Cancer 1995, 76, 727-735.
97. Lundin, M.; Nordling, S.; Roberts, P.J.; Lundin, J.; Carpelan-Holmström, M.; von Boguslawsky, K.; Haglund, C. Sialyl Tn is a frequently expressed antigen in colorectal cancer: No correlation with patient prognosis. Oncology 1999, 57, 70-76.
98. Nakagoe, T.; Sawai, T.; Tsuji, T.; Jibiki, M.; Nanashima, A.; Yamaguchi, H.; Yasutake, T.; Ayabe, H.; Arisawa, K. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients. Hepatogastroenterology 2003, 50, 696-699.
99. Akamine, S.; Nakagoe, T.; Sawai, T.; Tsuji, T.; Tanaka, K.; Hidaka, S.; Shibasaki, S.-I.; Nanashima, A.; Yamaguchi, H.; Nagayasu, T.; Yasutake, T. Differences in prognosis of colorectal cancer patients based on the expression of sialyl Lewisa, sialyl Lewisx and sialyl Tn antigens in serum and tumor tissue. Anticancer Res. 2004, 24, 2541-2546.
100. Soares, R.; Marinho, A.; Schmitt, F. Expression of sialyl-Tn in breast cancer. Correlation with prognostic parameters. Pathol. Res. Pract. 1996, 192, 1181-1186.
101. Kalaaji, A.N. Cytokine therapy in advanced melanoma. J. Drugs Dermatol. 2007, 6, 374-378.
102. MacLean, G.D.; Reddish, M.A.; Bowen-Yacyshyn, M.B.; Poppema, S.; Longenecker, B.M. Active specific immunotherapy against adenocarcinomas. Cancer Invest. 1994, 12, 46-56.
103. Hadden, J.W. The immunology and immunotherapy of breast cancer: an update. Int. J. Immunopharmacol. 1999, 21, 79-101.
104. Holmberg, L.A.; Sandmaier, B.M. Theratope vaccine (STn-KLH). Expert. Opin. Biol. Ther. 2001, 1, 881-891.
105. Mitchell, M.S. Cancer vaccines, a critical review--Part II. Curr. Opin. Investig. Drugs 2002, 3, 150-158.
106. Morse, M.A. Technology evaluation: Theratope, Biomira Inc. Curr. Opin. Mol. Ther. 2000, 2, 453-458.
107. Miles, D.; Roché, H.; Martin, M.; Perren, T.J.; Cameron, D.A.; Glaspy, J.; Dodwell, D.; Parker, J.; Mayordomo, J.; Tres, A.; Murray, J.L.; Ibrahim, N.K. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 2011, 16, 1092-1100.
108. Ragupathi, G.; Howard, L.; Cappello, S.; Koganty, R.R.; Qiu, D.; Longenecker, B.M.; Reddish, M.A.; Lloyd, K.O.; Livingston, P.O. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells. Cancer Immunol. Immunother. 1999, 48, 1-8.
109. MacLean, G.D.; Miles, D.W.; Rubens, R.D.; Reddish, M.A.; Longenecker, B.M. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J. Immunother. Emphasis. Tumor Immunol. 1996, 19, 309-316.
110. Miles, D.W.; Towlson, K.E.; Graham, R.; Reddish, M.; Longenecker, B.M.; Taylor-Papadimitriou, J.; Rubens, R.D. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br. J. Cancer 1996, 74, 1292-1296.
111. MacLean, G.D.; Reddish, M.A.; Koganty, R.R.; Longenecker, B.M. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immunother. Emphasis. Tumor Immunol. 1996, 19, 59-68.
112. Reddish, M.A.; MacLean, G.D.; Poppema, S.; Berg, A.; Longenecker, B.M. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol. Immunother. 1996, 42, 303-309.
113. Holmberg, L.A.; Sandmaier, B.M. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev. Vaccines 2004, 3, 655-663.
114. Mitchell, M.S. Immunotherapy as part of combinations for the treatment of cancer. Int. Immunopharmacol. 2003, 3, 1051-1059.
115. Limited, A.I. Cancer vaccine THERATOPE-Biomira. Drugs R. D. 2003, 4, 236-240.
116. Untch, M.; Ditsch, N.; Hermelink, K. Immunotherapy: new options in breast cancer treatment. Expert Rev. Anticancer Ther. 2003, 3, 403-408.
117. Ibrahim, N.K.; Murray, J.L. Clinical development of the STn-KLH vaccine (Theratope). Clin. Breast Cancer 2003, 3(Suppl. 4), S139-S143.
118. Miles, D.; Papazisis, K. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clin. Breast Cancer 2003, 3(Suppl. 4), S134-S138.
119. Gradishar, W.J.; Sahmoud, T. Current and future perspectives on fulvestrant. Clin. Breast Cancer 2005, 6 (Suppl. 1), S23-S29.
120. Holmberg, L.A.; Oparin, D.V.; Gooley, T.; Lilleby, K.; Bensinger, W.; Reddish, M.A.; MacLean, G.D.; Longenecker, B.M.; Sandmaier, B.M. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant. 2000, 25, 1233-1241.
121. Butts, C.A.; Mulder, K.E.; Fields, A.L.; Koski, S.; Scarfe, A.G.; Sawyer, M.B.; Au, H.-J.; Parker, J. Antibody responses to STn-KLH vaccine are produced in patients with metastatic colorectal cancer (CRC) receiving concurrent first-line chemotherapy (CX), ASCO Annual Meeting. In Proc. Am. Soc. Clin. Oncol., 2003 ASCO Annual Meeting, Chicago, IL, USA, 31 May-3 June 2003; Vol. 22, p. (abst. 684).
122. Mayordomo, J.; Tres, A.; Miles, D.; Finke, L.; Jenkins, H. Long-term follow-up of patients concomitantly treated with hormone therapy in a prospective controlled randomized multicenter clinical study comparing STn-KLH vaccine with KLH control in stage IV breast cancer following first-line chemotherapy. In J. Clin. Oncol. (Post-Meeting Edition), 2004 ASCO Annual Meeting, New Orleans, LA, USA, 5-8 June, 2004; Vol. 22, p. 2603.
123. Khanna, H.D.; Singh, S.; Agrawal, G.; Khanna, R.; Singh, L.P.; Khanna, R.; Khanna, S. Intra nuclear estrogen receptor status and its clinicopathological correlation in breast cancer patients. Cancer Biochem. Biophys. 1996, 15, 141-149.
124. Martin, P.M.; Rolland, P.H.; Jacquemier, J.; Rolland, A.M.; Toga, M. Multiple steroid receptors in human breast cancer. III. Relationships between steroid receptors and the state of differentiation and the activity of carcinomas throughout the pathologic features. Cancer Chemother. Pharmacol. 1979, 2, 115-120.
125. Braun, D.P.; Crist, K.A.; Shaheen, F.; Staren, E.D.; Andrews, S.; Parker, J. Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity. Am. J. Surg. 2005, 190, 570-571.
126. Julien, S.; Picco, G.; Sewell, R.; Vercoutter-Edouart, A.-S.; Tarp, M.; Miles, D.; Clausen, H.; Taylor-Papadimitriou, J.; Burchell, J.M. Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br. J. Cancer 2009, 100, 1746-1754.
127. Herlyn, D.; Koprowski, H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc. Natl. Acad. Sci. USA 1982, 79, 4761-4765.
128. Blixt, O.; Bueti, D.; Burford, B.; Allen, D.; Julien, S.; Hollingsworth, M.; Gammerman, A.; Fentiman, I.; Taylor-Papadimitriou, J.; Burchell, J.M. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res. 2011, 13, R25.
129. Monti, P.; Leone, B.E.; Zerbi, A.; Balzano, G.; Cainarca, S.; Sordi, V.; Pontillo, M.; Mercalli, A.; Di Carlo, V.; Allavena, P.; Piemonti, L. Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell. J. Immunol. 2004, 172, 7341-7349.
130. Lakshminarayanan, V.; Thompson, P.; Wolfert, M.A.; Buskas, T.; Bradley, J.M.; Pathangey, L.B.; Madsen, C.S.; Cohen, P.A.; Gendler, S.J.; Boons, G.-J. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc. Natl. Acad. Sci. USA 2012, 109, 261-266.
131. Murphy, K.; Travers, P.; Walport, M.; Janeway, C. Janeway's immunobiology; Garland Science: New York, NY, USA, 2012.
132. Silva, Z.; Konstantopoulos, K.; Videira, P.A. The role of sugars in dendritic cell trafficking. Ann. Biomed. Eng. 2012, 40, 777-789.
133. Steinman, R.M.; Hawiger, D.; Nussenzweig, M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003, 21, 685-711.
134. Adderson, E.E. Antibody repertoires in infants and adults: effects of T-independent and T-dependent immunizations. Springer Semin. Immunopathol. 2001, 23, 387-403.
135. Purcell, A.W.; McCluskey, J.; Rossjohn, J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 2007, 6, 404-414.
136. Avci, F.Y.; Kasper, D.L. How bacterial carbohydrates influence the adaptive immune system. Annu. Rev. Immunol. 2010, 28, 107-130.
137. Liu, C.-C.; Ye, X.-S. Carbohydrate-based cancer vaccines: target cancer with sugar bullets. Glycoconj. J. 2012, 29, 259-271.
138. O'Boyle, K.P.; Zamore, R.; Adluri, S.; Cohen, A.; Kemeny, N.; Welt, S.; Lloyd, K.O.; Oettgen, H.F.; Old, L.J.; Livingston, P.O. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn. Cancer Res. 1992, 52, 5663-5667.
139. Lo-Man, R.; Vichier-Guerre, S.; Bay, S.; Dériaud, E.; Cantacuzène, D.; Leclerc, C. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope. J. Immunol. 2001, 166, 2849-2854.
140. Gaidzik, N.; Kaiser, A.; Kowalczyk, D.; Westerlind, U.; Gerlitzki, B.; Sinn, H.P.; Schmitt, E.; Kunz, H. Synthetic Antitumor Vaccines Containing MUC1 Glycopeptides with Two Immunodominant Domains-Induction of a Strong Immune Response against Breast Tumor Tissues. Angew. Chem. Int. Ed. Engl. 2011, 50, 9977-9981.
141. Kagan, E.; Ragupathi, G.; Yi, S.S.; Reis, C.A.; Gildersleeve, J.; Kahne, D.; Clausen, H.; Danishefsky, S.J.; Livingston, P.O. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn. Cancer Immunol. Immunother. 2005, 54, 424-430.
142. Kaiser, A.; Gaidzik, N.; Westerlind, U.; Kowalczyk, D.; Hobel, A.; Schmitt, E.; Kunz, H. A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response. Angew. Chem. Int. Ed. Engl. 2009, 48, 7551-7555.
143. Crespo, H.J.; Cabral, M.G.; Teixeira, A.V.; Lau, J.T.Y.; Trindade, H.; Videira, P.A. Effect of sialic acid loss on dendritic cell maturation. Immunology 2009, 128, e621-631.
144. Videira, P.A. Departamento de Imunologia, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal, 2012, Unpublished observation.
145. Heimburg-Molinaro, J.; Lum, M.; Vijay, G.; Jain, M.; Almogren, A.; Rittenhouse-Olson, K. Cancer vaccines and carbohydrate epitopes. Vaccine 2011, 29, 8802-8826.
146. Yin, Z.; Huang, X. Recent Development in Carbohydrate Based Anti-cancer Vaccines. J. Carbohydr. Chem. 2012, 31, 143-186.
147. Clément, M.; Rocher, J.; Loirand, G.; Le Pendu, J. Expression of sialyl-Tn epitopes on beta1 integrin alters epithelial cell phenotype, proliferation and haptotaxis. J. Cell. Sci. 2004, 117, 5059-5069.
148. Schultz, M.J.; Swindall, A.F.; Bellis, S.L. Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Meta. Rev. 2012, Doi: 10.1007/s10555-012-9359-7, 15 June 2012, Epub ahead of print.
149. Dudley, M.E.; Wunderlich, J.R.; Yang, J.C.; Sherry, R.M.; Topalian, S.L.; Restifo, N.P.; Royal, R.E.; Kammula, U.; White, D.E.; Mavroukakis, S.A.; Rogers, L.J.; Gracia, G.J.; Jones, S.A.; Mangiameli, D.P.; Pelletier, M.M.; Gea-Banacloche, J.; Robinson, M.R.; Berman, D.M.; Filie, A.C.; Abati, A.; Rosenberg, S.A. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005, 23, 2346-2357.
150. Hollingsworth, M.A.; Swanson, B.J. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 2004, 4, 45-60.
151. Burdick, M.D.; Harris, A.; Reid, C.J.; Iwamura, T.; Hollingsworth, M.A. Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines. J. Biol. Chem. 1997, 272, 24198-24202.
152. Madan, R.A.; Arlen, P.M.; Gulley, J.L. PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin. Biol. Ther. 2007, 7, 543-554.
153. Liu, M.; Acres, B.; Balloul, J.-M.; Bizouarne, N.; Paul, S.; Slos, P.; Squiban, P. Gene-based vaccines and immunotherapeutics. Proc. Natl. Acad. Sci. USA 2004, 101(Suppl. 2), 14567-14571.
154. Bradbury, P.A.; Shepherd, F.A. Immunotherapy for lung cancer. J. Thorac. Oncol. 2008, 3, S164-170.
155. Beatson, R.E.; Taylor-Papadimitriou, J.; Burchell, J.M. MUC1 immunotherapy. Immunotherapy 2010, 2, 305-327.
156. Pinto, R.; Carvalho, A.S.; Conze, T.; Magalhães, A.; Picco, G.; Burchell, J.M.; Taylor-Papadimitriou, J.; Reis, C.A.; Almeida, R.; Mandel, U.; Clausen, H.; Söderberg, O.; David, L. Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation. J. Cell. Mol. Med. 2012, 16, 1474-1484.
157. Yang, E.; Hu, X.F.; Xing, P.X. Advances of MUC1 as a target for breast cancer immunotherapy. Histol. Histopathol. 2007, 22, 905-922.
158. Irimura, T.; Denda, K.; Iida, S.; Takeuchi, H.; Kato, K. Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity. J. Biochem. 1999, 126, 975-985.
159. Grote, T.; Logsdon, C.D. Progress on molecular markers of pancreatic cancer. Curr. Opin. Gastroenterol. 2007, 23, 508-514.
160. Hanisch, F.-G.; Ninkovic, T. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine. Curr. Protein Pept. Sci. 2006, 7, 307-315.
161. Ninkovic, T.; Hanisch, F.-G. O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes. J. Immunol. 2007, 179, 2380-2388.
162. Xu, Y.; Gendler, S.J.; Franco, A. Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J. Exp. Med. 2004, 199, 707-716.
163. Karsten, U.; Serttas, N.; Paulsen, H.; Danielczyk, A.; Goletz, S. Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1). Glycobiology 2004, 14, 681-692.
164. Pedersen, J.W.; Blixt, O.; Bennett, E.P.; Tarp, M.A.; Dar, I.; Mandel, U.; Poulsen, S.S.; Pedersen, A.E.; Rasmussen, S.; Jess, P.; Clausen, H.; Wandall, H.H. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int. J. Cancer 2011, 128, 1860-1871.
165. Cazet, A.; Julien, S.; Bobowski, M.; Burchell, J.; Delannoy, P. Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res. 2010, 12, 204.
166. Westerlind, U.; Kunz, H. Synthetic vaccines based on N-and O-glycopeptides-molecular tools for immunotherapy and diagnostics. In Carbohydrate Chemistry; Pilar Rauter, A.; Lindhorst, T., Eds.; Royal Society of Chemistry: Cambridge, UK, 2010; Vol. 36, pp. 1-37.
167. Niederhafner, P.; Reinis, M.; Sebestík, J.; Jezek, J. Glycopeptide dendrimers, part III: a review. Use of glycopeptide dendrimers in immunotherapy and diagnosis of cancer and viral diseases. J. Pept. Sci. 2008, 14, 556-587.
168. Slovin, S.F.; Ragupathi, G.; Fernandez, C.; Diani, M.; Jefferson, M.P.; Wilton, A.; Kelly, W.K.; Morris, M.; Solit, D.; Clausen, H.; Livingston, P.; Scher, H.I. A polyvalent vaccine for high-risk prostate patients: "are more antigens better?"Cancer Immunol. Immunother. 2007, 56, 1921-1930.
169. Gray, A.; Yan, L.; Kast, W.M. Prevention is better than cure: the case for clinical trials of therapeutic cancer vaccines in the prophylactic setting. Mol. Interv. 2010, 10, 197-203.
170. Jaini, R.; Kesaraju, P.; Johnson, J.M.; Altuntas, C.Z.; Jane-Wit, D.; Tuohy, V.K. An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat. Med. 2010, 16, 799-803.
171. Altuntas, C.Z.; Jaini, R.; Kesaraju, P.; Jane-wit, D.; Johnson, J.M.; Covey, K.; Flask, C.A.; Dutertre, M.; Picard, J.-Y.; Tuohy, V.K. Autoimmune mediated regulation of ovarian tumor growth. Gynecol. Oncol. 2012, 124, 98-104.
172. Adams, M.; Borysiewicz, L.; Fiander, A.; Man, S.; Jasani, B.; Navabi, H.; Lipetz, C.; Evans, A.S.; Mason, M. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 2001, 19, 2549-2556.